Shares of Janux (NASDAQ:JANX) shot up 48% in post-market trading Monday after the company reported positive data from a Phase 1 study for its PSMA-targeting therapy candidate JANX007 in the treatment of metastatic castration-resistant prostate cancer, or mCRPC.

Janux (